← Mendus AB (IMMU.ST) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Mendus AB (IMMU.ST)
Pharmaceutical Preparations · market cap $41M · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
2
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Mendus AB (IMMU.ST) is a small Swedish pharmaceutical company with 19 employees and a market cap of approximately $36M, developing cancer immunotherapies. Its two clinical-stage assets are Intuvax (ilixadencel) in Phase 2 for metastatic renal cell carcinoma and DCP-001 in Phase 2 for acute myeloid leukemia. The company has a single analyst covering it with a buy consensus and a price target of 16, but the facts provided contain significant data gaps across financials, cash position, and near-term catalysts.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Intuvax (INN: ilixadencel) | Phase 2 | Renal Cell Carcinoma, Metastatic |
| DCP-001 | Phase 2 | Acute Myeloid Leukemia (AML) |
Price & technical context
3-month
-4.6%
6-month
+39.6%
12-month
-7.5%
52-wk range
$3.95–$7.47
vs 50-day MA
-9.1%
vs 200-day MA
+9.1%
Realized vol
70.8%
Max drawdown
-62.6%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for IMMU.ST (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.